BMO Capital Reaffirms Their Hold Rating on Alnylam Pharma (ALNY)

BMO Capital analyst Gary Nachman maintained a Hold rating on Alnylam Pharma (ALNYResearch Report) today and set a price target of $175.00. The company’s shares closed last Friday at $148.79.

According to TipRanks.com, Nachman has 0 stars on 0-5 stars ranking scale with an average return of -4.4% and a 42.7% success rate. Nachman covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals, Jazz Pharmaceuticals, and Horizon Therapeutics.

Currently, the analyst consensus on Alnylam Pharma is a Strong Buy with an average price target of $210.53, implying a 41.0% upside from current levels. In a report issued on January 28, Leerink Partners also maintained a Hold rating on the stock with a $109.00 price target.

See the top stocks recommended by analysts >>

Alnylam Pharma’s market cap is currently $18.04B and has a P/E ratio of -21.15.

Based on the recent corporate insider activity of 37 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ALNY in relation to earlier this year. Most recently, in December 2021, John Maraganore, the CEO of ALNY bought 5,367 shares for a total of $399,829.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases. The company was founded by John Kennedy Clarke, Paul R. Schimmel and Phillip A. Sharp on June 14, 2002 and is headquartered in Cambridge, MA.

Read More on ALNY:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed